J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $9
Novavax Analyst Ratings
Jefferies Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $25
Cautious Optimism for Novavax Amid Clinical Hold Challenges
Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained
Novavax Analyst Ratings
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Raises Target Price to $26
B. Riley Raises Price Target on Novavax to $26 From $23, Keeps Buy Rating
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Jefferies Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $31
Novavax Analyst Ratings
Jefferies Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $31
Jefferies Sticks to Their Buy Rating for Novavax (NVAX)
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $23
Strong Buy Rating for Novavax: Strategic Positioning and Enhanced COVID-19 Vaccine Efficacy
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $23
Buy Rating Affirmed for Novavax Amid Strong Vaccine Candidate Performance and Competitive Edge
Novavax (NVAX) Gets a Sell From J.P. Morgan
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Raises Target Price to $9
Novavax Analyst Ratings